Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma

European Journal of Surgical Oncology

Volumn 35, Issue 9, 2009, Pages 980-985

  Yano, H ^a   Moran, B J ^a   Cecil, T D ^a   Murphy, E M ^a  

^a BASINGSTOKE AND NORTH HAMPSHIRE HOSPITAL   (United Kingdom)

Author keywords

Cytoreductive surgery; Intraperitoneal chemotherapy; Peritoneal mesothelioma

Indexed keywords

CISPLATIN; DOXORUBICIN; TUMOR MARKER;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASCITES; CANCER SURVIVAL; CHEST INFECTION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LAPAROTOMY; LUNG EMBOLISM; MALE; MORTALITY; OUTCOME ASSESSMENT; PERITONEUM MESOTHELIOMA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; SURGICAL APPROACH; SURGICAL TECHNIQUE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MESOTHELIOMA; MIDDLE AGED; PATIENT SELECTION; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 68049144538     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2008.09.010     Document Type: Article

References (30)

1. Miller J., and Wynn W. A malignant tumour arising from the endothelium of the peritoneum and producing mucoid ascitic fluid. J Pathol Bacteriol 12 (1908) 267-278
2. Whitaker D., Manning L., Robinson B., and Shilkin K. The pathobiology of the mesothelium. In: Henderson D., Shilkin K., Langlois S., and Whitaker D. (Eds). Malignant mesothelioma (1992), Hemisphere Publishing, New York 25-68
3. Antman K.H., Osteen R.T., Klegar K.L., et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet 2 (1985) 977-981
4. Berry G., de Klerk N.H., Reid A., et al. Malignant pleural and peritoneal mesotheliomas in former miners and millers of crocidolite at Wittenoom, Western Australia. Occup Environ Med 61 (2004) e14
5. Hodgson J.T., McElvenny D.M., Darnton A.J., Price M.J., and Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92 (2005) 587-593
6. Wagner J.C., Sleggs C.A., and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17 (1960) 260-271
7. Carbone M., Kratzke R.A., and Testa J.R. The pathogenesis of mesothelioma. Semin Oncol 29 (2002) 2-17
8. Gilks B., Hegedus C., Freeman H., Fratkin L., and Churg A. Malignant peritoneal mesothelioma after remote abdominal radiation. Cancer 61 (1988) 2019-2021
9. Riddell R.H., Goodman M.J., and Moossa A.R. Peritoneal malignant mesothelioma in a patient with recurrent peritonitis. Cancer 48 (1981) 134-139
10. Roushdy-Hammady I., Siegel J., Emri S., Testa J.R., and Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357 (2001) 444-445
11. Acherman Y.I., Welch L.S., Bromley C.M., and Sugarbaker P.H. Clinical presentation of peritoneal mesothelioma. Tumori 89 (2003) 269-273
12. Kass M.E. Pathology of peritoneal mesothelioma. Cancer Treat Res 81 (1996) 213-225
13. Karakousis C.P., Seddiq M., and Moore R. Malignant mesotheliomas and chemotherapy. J Surg Oncol 15 (1980) 181-185
14. Markman M., and Kelsen D. Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 118 (1992) 547-550
15. Fizazi K., Doubre H., Le Chevalier T., et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 21 (2003) 349-354
16. Lee J.M., Bruckner H.W., Szrajer L., Brenne U., Schindelheim G., and Andreotti P.E. Taxol inhibits growth of mesothelioma xenografts. Anticancer Res 15 (1995) 693-696
17. Feldman A.L., Libutti S.K., Pingpank J.F., et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21 (2003) 4560-4567
18. Rogoff E.E., Hilaris B.S., and Huvos A.G. Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer 32 (1973) 656-664
19. Lederman G.S., Recht A., Herman T., Osteen R., Corson J., and Antman K.H. Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment. Cancer 59 (1987) 1882-1886
20. Deraco M., Casali P., Inglese M.G., et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol 83 (2003) 147-153
21. Loggie B.W., Fleming R.A., McQuellon R.P., Russell G.B., Geisinger K.R., and Levine E.A. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 67 (2001) 999-1003
22. Yan T.D., Haveric N., Carmignani C.P., Chang D., and Sugarbaker P.H. Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 103 (2005) 839-849
23. Almudevar Bercero E., Garcia-Rostan Perez G.M., Garcia Bragado F., and Jimenez C. Prognostic value of high serum levels of CA-125 in malignant secretory peritoneal mesotheliomas affecting young women. A case report with differential diagnosis and review of the literature. Histopathology 31 (1997) 267-273
24. Churg A., Colby T.V., Cagle P., et al. The separation of benign and malignant mesothelial proliferations. Am J Surg Pathol 24 (2000) 1183-1200
25. Weiss S.W., and Tavassoli F.A. Multicystic mesothelioma. An analysis of pathologic findings and biologic behavior in 37 cases. Am J Surg Pathol 12 (1988) 737-746
26. Park B.J., Alexander H.R., Libutti S.K., et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 6 (1999) 582-590
27. Sebbag G., Yan H., Shmookler B.M., Chang D., and Sugarbaker P.H. Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 87 (2000) 1587-1593
28. Mohamed F., and Sugarbaker P.H. Peritoneal mesothelioma. Curr Treat Options Oncol 3 (2002) 375-386
29. Robinson B.W., Creaney J., Lake R., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362 (2003) 1612-1616
30. Robinson B.W., Creaney J., Lake R., et al. Soluble mesothelin-related protein-a blood test for mesothelioma. Lung Cancer 49 Suppl. 1 (2005) S109-S111